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Abstract
Introduction Evidence-based treatment guidelines have
undoubtedly advanced medical practice and supported opti-
mal management of acromegaly, but their application may be
hampered by limited access to the latest treatment options.
Methods In this retrospective, narrative review, the authors
revisited existing treatment guidelines for acromegaly in Latin
America. These were considered in conjunction with pub-
lished evidence chosen at the authors’ discretion.
Findings In a socially and economically diverse region,
such as Latin America, any regional practice guidelines need
to appreciate that recommended treatment options, such as
surgery by expert pituitary surgical teams and drug thera-
pies, especially somatostatin analogs, are often not available
due to limited resources. In these instances, physicians may
be obliged to apply less effective therapeutic options.
Conclusions The current article looks at the practical
aspects of acromegaly management in Latin America and
discusses this in the context of existing guidelines. Fur-
thermore, we consider potential strategies to make better
use of resources through combination and multimodal
approaches to treatment.
Keywords Acromegaly  Latin America 
Somatostatin analogs  Dopamine agonists 
Pegvisomant  Guidelines
Introduction
Diagnosing and managing acromegaly can be a challenge,
even in situations where clinicians have access to all the latest
diagnostic and treatment modalities (see other articles in this
issue [1–4]). This can be complicated further if diagnosis is
delayed and/or access to healthcare resources is limited.
Failure to identify acromegaly early and to provide optimal
disease management often can lead to significant morbidity,
severely impaired quality of life and reduced life-expectancy.
Latin America (with between 550 and 600 million people
in total) is a region with wide variations in development,
poverty, income inequality, literacy, and life expectancy
both between and within individual countries [5]. National
health care systems in Latin American countries also vary
widely in their organizational structure and provision of
healthcare services [6]. Access to healthcare resources varies
widely not only among countries, but also within countries
and even within cities or provinces.
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Economic considerations to prioritize resource alloca-
tion decisions are increasingly being used in Latin Amer-
ica, but the use and application of formal Health Economic
Evaluations or Health Technology Assessments remains
suboptimal [6, 7]. Although countries previously relied on
technology assessment reports from outside the Latin
America region, there is increasing use of region-specific
reports, which are considered more relevant [6].
Evidence-based treatment guidelines have undoubtedly
advanced medical practice and supported optimal pre-
scribing for acromegaly, but tend to be developed within
the context of optimal access to the latest treatment
options. Against this background of diversity and disparity
in Latin America, any regional practice guidelines for the
management of acromegaly need to appreciate that the
recommended options may often not be available due to
limited resources.
Epidemiology of acromegaly in Latin America
Although epidemiologic data are relatively limited over the
Latin America region as a whole, national acromegaly reg-
istries are starting to provide a reliable picture of diagnostic
and treatment patterns, as well estimates for the prevalence
of the disease [8, 9]. For instance, the Mexican Acromegaly
Registry (EpiAcro), which now includes over 1,400 patients,
gives an estimated prevalence of 14 cases per million, which
is lower than other parts of the world, suggesting under
diagnosis [8, 9]. Time between onset and diagnosis ranged
from 5 to 17 years, and approximately one-third of patients
had an invasive tumor at diagnosis. Pituitary surgery was the
most common primary treatment option (73 % of patients),
whereas radiosurgery was the primary treatment option in
only 3 %. The remainder received pharmacological therapy
with somatostatin analogs (SSAs) (15 %) or dopamine
agonists (9 %). Approximately 60 % of patients undergoing
primary surgery did not achieve biochemical remission and
required secondary therapy. For secondary treatment, 36 %
had radiosurgery, 36 % received SSAs, 19 % received
dopamine agonists and 26 % had surgery. The latest data
suggest that 34 % of patients in the registry are in bio-
chemical remission, 40 % have active disease and 27 % are
stable on pharmacological therapy.
Guidelines for the management of acromegaly
Since 2000, the Acromegaly Consensus Group has developed
several international guidelines and consensus statements
regarding the management of acromegaly [10–14]. The latest
major update to these guidelines was published in 2009, based
upon evidence available in 2007, and a further consensus on
diagnosis and treatment of acromegaly complications was
published in 2012 [14, 15]. A meeting held in Mexico City in
2007 led to expert panel recommendations on the manage-
ment of acromegaly specifically in Latin America, and
these were published in 2010 [16]. Guidelines have also
been developed at the national level in Mexico and Brazil
[17, 18].
All the latest versions of these guidelines and consensus
statements generally recommend either surgery or, if there is
a low probability of surgical cure, SSAs as primary therapy
in acromegaly (see Fig. 1 for the algorithm developed by the
Latin American Expert Panel [16]). The SSAs are consid-
ered the pharmacological treatment of choice because they
fulfill all the requirements for the primary treatment of
acromegaly by reducing tumor volume, controlling disease
symptoms and achieving biochemical control in the majority
of patients. Nevertheless, it should be pointed out that the
best results were obtained in patients with mild-to-moderate
serum GH elevation. Furthermore, a selection bias could
occur in retrospective studies due to the withdrawal of
unresponsive patients. Evidence to support the use of SSAs
as the primary pharmacological therapeutic option is now
extensive and includes several studies involving Latin
American populations [19–23]. Furthermore, all the guide-
lines generally recommend SSA therapy as the next line of
treatment in patients with insufficiently controlled GH
secretion after surgery.
In the settings above, dopamine agonists (principally ca-
bergoline) are generally reserved for patients with relatively
low GH and IGF-I concentrations or those in whom an oral
drug is preferred over injectable therapy (as is the case for all
SSA formulations). The GH receptor antagonist pegvisomant
is generally reserved for third-line therapy. Radiosurgery is
considered to be an option in selected cases when no disease
control is achieved with surgery and pharmacological ther-
apy, especially if pegvisomant is not available.
While considering the recommendations highlighted
above, one key issue raised by the Latin American Panel is
that of limited access to resources at the local level [16].
This message was reinforced repeatedly by the Panel, e.g.:
• ‘‘Since not all the diagnostic tools and treatment
options are available in all Latin American countries,
physicians need to adapt their clinical management
decisions to the available local resources and thera-
peutic options’’.
• ‘‘…treatment of patients with acromegaly in Latin
America is influenced by local issues of cost, avail-
ability and expertise of pituitary neurosurgeons, which
should dictate therapeutic choices.’’
• ‘‘…a range of management approaches may not be
available for many patients with acromegaly and the
feasibility and cost should be considered in the
implementation of local guidelines.’’
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• ‘‘Access to SSAs is a key issue in Latin America, as
treatment is not always subsidized by government
agencies.’’
• ‘‘Physicians in Latin America should tailor appropriate
treatments or combinations for each patient based on
the clinical presentation and availability of resources’’.
• ‘‘…judgment is required to indicate the first-line
therapy, taking into account the local experience
and availability of resources.’’
Revisiting the expert panel recommendations
on the management of acromegaly in Latin America
Little has changed in terms of new therapies in the
market since the publication of those recommendations
(although there may have been changes in access to
individual therapeutic options at the local level). How-
ever, guidance was minimal regarding the best approach
to take in cases where access to resources is restricted,
although it was noted that ‘‘Radiotherapy may be indi-
cated in selected cases….when local issues of cost pre-
clude other therapies.’’ The preceding section summarizes
the broad consensus panel efforts regarding recommen-
dations for the management of acromegaly in Latin
America. The following sections provide our own sug-
gestions on how to gain the most benefit from available
resources within the context of those recommendations.
This may assist in providing a more practical, relevant
and flexible approach to acromegaly treatment across
Latin America.
In view of the recommendations that SSAs generally
represent the first-choice pharmacological therapy in acro-
megaly, it is worth highlighting the way in which this ther-
apy can be optimized and costs reduced [24]. Addition of
Microadenoma ( 1 cm) OR
Surgically resectable macroadenoma 
( 1 cm) OR Presence of visual field defects
AND
Availability of an experienced pituitary 
neurosurgeon
Patient refuses surgery OR
Clinical contraindication to surgery OR
Cavernous sinus invasion OR
Limited chance of surgical cure OR






Transsphenoidal resection First-line therapy with Somatostatin Analogs 
A
Minimal or moderate residual 
disease Large residual adenoma
Inadequate control after 
maximal surgical debulking and 
maximal use of Somatostatin Analogs
Disease control
Add Cabergoline to maximal dose of 
Somatostatin Analog
Add Pegvisomant* to maximal dose of 
Somatostatin Analog
No disease control Disease control No disease control
Radiotherapy
B
Fig. 1 Treatment algorithm for
choosing first-line therapy in
Latin American patients with
newly diagnosed acromegaly
(a) or those uncontrolled after
surgery and SSAs (b). *Because
pegvisomant is not available in
all Latin American countries,
radiotherapy might be
considered as an additional
treatment option for patients not
controlled after maximal doses
of somatostatin analogs and/or
cabergoline. (Reproduced with
permission from [16])
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cabergoline (a less effective, but also less expensive oral
agent that is widely available in Latin America) may
improve response in patients uncontrolled with SSAs alone,
thus improving the cost-effectiveness of these agents [24–
27]. Although pegvisomant is expensive, requires daily
injections and has only limited availability across Latin
America, it can be effective as add-on therapy in partial
responders to SSAs and there are several other potential
advantages to using this combination in selected patients
[24, 28, 29]. For instance pegvisomant/SSA combination
therapy may be associated with 1) improved insulin sensi-
tivity and quality of life compared with using SSAs alone, 2)
better control of tumor size compared with pegvisomant
alone, and 3) reduced pegvisomant doses and thus cost
savings [24, 28, 29]. For acromegalic women with mild IGF-
1 elevation, estrogens represent an inexpensive alternative to
pegvisomant, as they act as a post-receptor noncompetitive
GH antagonist by stimulating hepatic socs2; however, the
risk of thrombosis should be taken into account [30].
In centers with sufficient surgical expertise, surgical
reduction of tumor mass can improve the outcome of SSA
treatment in acromegalic patients resistant to primary
therapy with SSAs [24, 31]; similarly, SSA treatment may
improve surgical outcomes [32]. Nevertheless, access to
skilled surgeons should not dictate the choice of therapy, if
pharmacological treatment is indicated. In well-controlled
patients, it may be possible to increase the interval between
doses without losing efficacy [33]. In a small subset of
patients, it may also be possible to permanently discontinue
SSA therapy, suggesting that these agents might provide
permanent beneficial functional changes in GH release (at
least in some patients) [34].
Cabergoline may be seen as an alternative (albeit less
effective) low-cost pharmacological treatment in situa-
tions where SSAs are not available. However, it should be
emphasized that this remains a suboptimal first choice and
health authorities should be encouraged to improve access
to recommended pharmacological therapies (i.e., SSAs).
Radiosurgery and modern external beam radiotherapy can
be an effective, low-cost and reasonably safe means of
controlling acromegalic activity, although it has a long
efficacy latency period [35, 36]. However, it should be
emphasized that the choice of radiation techniques must
be based on tumor characteristics and if possible should
be performed using stereotactic devices [37]. Therefore,
health authorities should be aware of the cost/benefit ratio
of less efficacious therapies, which, albeit leading to
potential savings, may be hampered by the social and
economic burden of co-morbidities present in uncon-
trolled acromegalic patients, as well as, in the case of
radiotherapy, the costs of full pituitary hormone replace-
ment in the frequent cases of progression to
panhypopituitarism.
Other factors that may contribute to improved care
in acromegaly in Latin America
Delayed diagnosis is a problem in many parts of the world,
including Latin America [8, 9, 38, 39]. Consequently,
many patients present with advanced disease that may not
be suitable for surgery, thus limiting treatment options.
There is, therefore, a need to increase awareness about
acromegaly—this has the potential to increase the chances
of early diagnosis and promote early referral to expert
centers, thus increasing treatment options, improving long-
term outcomes and reducing costs [40]. Education of
general practitioners and the adoption of simple screening
techniques based on phenotypic alterations may be one
cost-effective method for identifying acromegaly early
[41]. Medical students, nurses, and the general public may
also be good candidates for increased awareness programs.
Implementation of support networks to provide adequate
patient follow-up is another important component of
acromegaly management. Patients on pharmacological
therapy require life-long treatment, but compliance can be
poor and many patients will not receive adequate long-term
therapy if follow-up support is insufficient [42]. Further-
more, a significant proportion of patients will change their
biochemical status during long-term follow-up after sur-
gery and may require a modification of management
strategies [43].
Finally, it should be stressed that diagnosis and man-
agement of acromegaly is complex and requires the
involvement of multidisciplinary expert teams. As such,
the comprehensive care, education and support of patients
with acromegaly are best carried out in designated Pituitary
Centers of Excellence (COE) [44]. Increasing access to
COEs across Latin America is thus a key aspect of
improving care in the region.
Conclusions
One of the greatest challenges in providing consensus rec-
ommendations regarding the management of acromegaly in
Latin America is the diversity of access to treatment and
reimbursement policies across this large population of
between 550 and 600 million. The wide variations in access
to healthcare resources across Latin America, which may
manifest in terms of access to surgical and/or pharmaco-
logical resources and the availability of adequate patient
support networks, make it difficult to provide pan-regional
recommendations for the management of acromegaly.
In some countries, the availability and cost of SSAs and
other drugs, such as pegvisomant, as well as the availability
of surgical expertise, are critical issues. Thus, some key
recommendations can only be followed when these
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resources are available and physicians may be obliged to
apply therapeutic options that are not indicated by the
international guidelines.
In the absence of access to first line recommended
pharmacological therapy (i.e., SSAs), physicians may have
to rely on less expensive, less effective drugs (most notably
cabergoline) or other less well-tolerated treatment modal-
ities (e.g., radiosurgery). Nevertheless, opportunities exist
for more flexible use of first choice therapies, such as
SSAs, in order to optimize treatment and reduce costs,
although economic outcome data are lacking. There is also
a common need across countries to increase awareness
about acromegaly—this could improve early diagnosis and
lead to improved outcomes and reduced costs.
In conclusion, delayed diagnosis and limited access to
healthcare resources can compromise optimal management
of patients with acromegaly. This situation may be par-
ticularly notable in parts of Latin America due to the
economic and social diversity across the region. Although
opportunities exist to improve management through opti-
mal use of existing limited healthcare resources, there is a
need for increased access to recommended therapies,
especially SSAs. Furthermore, the creation of regional
acromegaly patient registries, such as EpiAcro, should help
to improve understanding of diagnostic and therapeutic
trends in different regions of Latin America.
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